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Abstract
Background: Human enterovirus (EV) and parechovirus (HPeV) are significant causes of encephalitis and meningitis
in children. The aim of this study was to determine the prevalence, type and viral RNA concentration of EV and
HPeV in cerebrospinal fluid (CSF) samples in an unselected cohort of patients <18 years admitted to Bonn university
hospital from 1998 to 2008.
Methods: A total of 327 CSF samples from 327 patients were retrospectively tested by real-time reverse-transcriptase
PCR (RT-PCR) for EV and HPeV, and by real-time PCR for cytomegalovirus (CMV), herpes simplex virus 1/2 (HSV), and
varizella zoster-virus (VZV). Samples had been submitted for routine virological work-up due to suspected meningitis or
encephalitis and had been stored at −20 °C hereafter. Positive samples for EV and HPeV were sequenced within the
gene encoding the VP1 region (EV), the VP2 and the VP3/VP1 junction region (HPeV).
Results: The overall prevalence was 4.3 % (14/327) for EV, 0.6 % (2/327) for HPeV, and 0.3 % (1/327) for HSV and VZV,
respectively. CMV was not detected in this cohort. In children less than 3 months of age the prevalence was 7.7 %
(2/26) for EV and 7.7 % (2/26) for HPeV, respectively. Frequency of EV detection ranged from 0 to 12 % per year and
highest rates were observed from June to September. All typed EV belonged to species B. Both HPeV infections were
detected in the fall of 2008 and were typed as HPeV genotype 3. Viral RNA concentrations were highest in patients
with HPeV infection, followed by echovirus 30 and other EV. In total, 86 % (12/14) of EV infections presented as aseptic
meningitis, whereas both HPeV infections presented as severe sepsis-like illness.
Conclusions: EV and HPeV were equally prevalent in children <3 months of age. Beyond the detection of EV and
HPeV, the determination of viral RNA concentration and typing of EV and HPeV might prove beneficial for patient
management and public health.
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Background
Human enteroviruses (EV) and parechovirus (HPeV) be-
long to the highly diversified family Picornaviridae and
constitute an important cause of central nervous system
(CNS) infections, meningitis and encephalitis, and
sepsis-like illness in children worldwide [1–3]. EV can be
grouped into 4 genetically distinct species, EV-A to D.
The most commonly detected EV associated with menin-
gitis belong to EV species B (including echoviruses, cox-
sackievirus (CV)-A9, and CV-B). Continued surveillance
and monitoring of EV evolution is important not only for
public health (EV disease association, identification of novel
variants), but also for patient management (isolation mea-
sures, treatment with IVIG). In 1997 an EV-A71 sparked an
ongoing epidemic across the Asia-Pacific region and is as-
sociated with hand, foot, and mouth disease accompanied
by severe neurological complications [4]. Recently, an EV-
D68 emerged and caused considerable morbidity and
mortality among children worldwide [5, 6]. For HPeV at
least 16 genotypes have been described to date, most of
them only recently (www.picornastudygroup.com). In
particular, HPeV genotype 3 (HPeV3) infections tend to be
more severe (including sepsis-like illness) compared to
infections with other HPeV genotypes [7].
The mainstay of laboratory diagnostics for EV and HPeV
infection depends on real-time reverse-transcription-PCR
(RT-PCR), which has considerably improved the detection
of EV as well as HPeV [8]. However, HPeV infection is still
reported infrequently and is most likely under-diagnosed
in Germany and elsewhere. Information on the epidemi-
ology over longer time periods and virus concentrations
for EV and especially HPeV in cerebrospinal fluid (CSF)
samples is lacking at large.
The aim of this study was to determine the prevalence,
types and RNA concentrations of EV and HPeV in an
unselected panel of CSF samples collected from pediatric
patients with a clinical suspicion of meningitis/encephal-
itis or late-onset sepsis with neurological symptoms ad-
mitted at a large university hospital over a 10-year period
to assess the role of these pathogens in pediatric disease.
Results
Median patient age was 8.0 years (range, 8 days to 17 years).
Eight percent of patients (26/327) were under the age of
3 months. An overall prevalence of 5.5 % (18/327) for any
viral pathogen was determined by real-time reverse-
transcriptase PCR (EV, HPeV) and real-time PCR (CMV,
HSV, VZV), respectively. EV was the most prevalent patho-
gen with 3.4 % (11/327) using the assay described by
Verstrepen et al. [9]. Upon use of the assay by Dierssen et
al. [10] prevalence increased by a quarter to 4.3 % (14/
327) (9 male, 5 female). In children less than 3 months of
age 7.7 % (2/26) tested positive for EV with both EV
assays (Verstrepen et al. and Diessen et al.) yielding
congruent positive results. For HPeV an overall prevalence
of 0.6 % (2/327) was determined (one female, one male).
Both HPeV RT-PCR assays applied yielded congruent re-
sults. If children older than 3 months of age were excluded
from the analysis, the prevalence of HPeV raised to 7.7 %
(2/26) similar to that of EV. One individual patient was
positive for HSV-1 (6 year-old male) and another for VZV
(4 year-old male) as determined by real-time PCR yielding
an overall prevalence of 0.3 % for each virus. Clinical
information was lacking for these two patients. Cyto-
megalovirus was not detected (0/327).
Since a seasonal pattern of occurrence for EV and
HPeV has been described cumulative detection rates
were plotted from January through December (Fig. 1).
For EV highest rates were observed in the summer
months from June to September. No EV detections were
seen in the years 1998, 1999, 2003 and 2006 (Table 1).
The two HPeV cases were detected in October and
November 2008, respectively. The HSV positive sample
was detected in January 2008 and the VZV positive one in
May 2007.
To further characterize the EV positive CSF samples
the VP2 region was partially sequenced. All EV for which
sequencing was successful (n = 10) belonged to EV
species B. In detail, six samples were echovirus 30, one
was echovirus six, one echovirus 13, one CV-B3, and
one was CV-B6. Of note, in one patient in whom typing
of the CSF sample was unsuccessful, EV-30 RNA could
be identified in a corresponding stool sample. This
sample was rated as EV-30 in all subsequent analyses.
All EV-30 positive samples were randomly scattered
throughout the entire study period. A total of three sam-
ples with EV concentrations of 3.3, 3.8, and 5.9 log10 RNA
copies/ml, respectively, remained refractory to typing.
Sequencing failed in CSF samples from two patients due to
rather low RNA concentrations. In the sample with the
highest viral RNA concentration no leftover impeded
Fig. 1 Monthly distribution of positive samples. Shown is the
cumulative number of positives samples in each month from
January to December. Each viral pathogen detected (HPeV, EV,
HSV, VZV) is indicated by a different bar
Vollbach et al. Virology Journal  (2015) 12:199 Page 2 of 6
typing. Sequencing of the VP1/VP3 region of the HPeV
positive samples yielded HPeV3 in both cases. Both
HPeV3 samples lacked a RGD motif in the VP1/2A
junction region.
In a next step, virus RNA concentrations of EV and
HPeV in CSF samples were analyzed. The mean virus
concentration of the EV positive samples was 4.3 log10
RNA copies/ml [95 % confidence interval (CI) 3.9–4.7
log10 RNA copies/ml]. For further analysis two groups
of EV-positive samples were compared. One group com-
prised samples with EV-30 (n = 7) and the second group
all other non EV-30 EV samples (n = 4) in which typing
was successful. Mean virus concentration in the first
group was 4.4 log10 RNA copies/ml, in the latter
group 4.2 log10 RNA copies/ml (Mann-Whitney U-
test, p >0.05).
An HPeV RNA concentration of 5.3 log10 RNA
copies/ml was measured in a 5-week-old child and a
concentration of 4.4 log10 RNA copies/ml in a 1-week-old
neonate, respectively. Next, viral loads between echovirus
30 (n = 7), all other typed non EV-30 EV positive samples
(n = 4) and both HPeV positive samples were compared.
Mean log10 viral RNA concentrations of EV-30, other
typed non EV-30 EV, and HPeV (4.9 log10 RNA copies/
ml) samples were not significantly different as assessed by
one-way ANOVA (Fig. 2). Of note, mean interval between
symptom onset and drawing of CSF was 0.4 days for EV
positive samples and 4.5 days for HPeV positive samples
(p = 0.002, two-tailed t-test). Of note, in the 5-week-old
child with HPeV infection a second lumbar puncture was
performed on day 7 after symptom onset upon clinical
deterioration (periodic breathing, lack of spontaneous
movement). The first lumbar puncture was performed on
day 1 of symptoms (hypothermia, sucking weakness, and
reduced general condition) but CSF was used up for other
testing. Mean virus concentrations of typed EV (n = 2) and
HPeV (n = 2) in children <3 months of age were not
significantly different (4.5 log10 RNA copies/ml versus 4.9
log10 RNA copies/ml, p <0.05, two-tailed t-test).
Mean age of children with EV-30 infection was
5.1 years (range, 1–9), 1.6 years (range, 3 months-6 years)
for those with non EV-30 EV infection, and 3 weeks for
those with HPeV3 infection. Aseptic meningitis was
diagnosed in 12/14 (86 %) patients with EV infection,
but not in patients with HPeV infection (Table 2). The
indication for lumbar puncture (i.e. aseptic meningitis or
encephalitis or other neurological symptoms) could not
unambiguously be retrieved for one child with EV infec-
tion, for another child with EV infection fever, headache,
meningism without pleocytosis was recorded. No clinical
signs of encephalitis were reported in those with EV in-
fection, but in one child with HPeV infection. Clinically,
both infants positive for HPeV displayed sepsis-like
illness. In the 1-week-old neonate this included reduced
general condition, sucking weakness, fever, and on
day 2 tonic-clonic seizures. Cranial ultrasound showed
hyperechogenicity, slurred gyrification, and hyperemia.
The 5-week-old infant first presented with hypothermia,
sucking weakness, reduced general condition, rash, and
later developed respiratory distress. No fatal outcome was
observed in the entire study cohort.
Discussion
In our cohort, we could show that HPeV3 is equally
prevalent to EV in infants less than 3 months of age,
which has not been observed in other studies so far.
Previous studies showed a prevalence of HPeV in CSF
Table 1 Proportion of samples positive for EV, HPeV, HSV, and
VZV in CSF samples collected from 1998 to 2008
Proportion (%) of virus-positive samples
Year Number of patients EV HPeV HSV VZV
1998 11 0 0 0 0
1999 12 0 0 0 0
2000 27 3 (11.1) 0 0 0
2001 27 1 (3.7) 0 0 0
2002 31 1 (3.2) 0 0 0
2003 23 0 0 0 0
2004 24 3 (12.5) 0 0 0
2005 34 1 (2.9) 0 0 0
2006 42 0 0 0 0
2007 47 2 (4.2) 0 0 1 (2)
2008 49 3 (6.1) 2 (4.1) 1 (2) 0
Total 327 14 (4.3) 2 (0.6) 1 (0.3) 1 (0.3)
Fig. 2 Viral RNA concentrations. Log10 RNA concentration per ml
CSF in samples positive for echovirus 30, non E-30 EV, and HPeV,
respectively. Virus concentrations are given on a log scale on the
y-axis. Each dot represents 1 specimen. Horizontal lines represent
median values for each sample group. Outer horizontal lines
represent the 95 % CI
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samples ranging from 0 to 17 % [11, 12]. However, studies
differed by inclusion criteria, study design, and demo-
graphic characteristics. In our study we used an unbiased
approach and included all CSF samples which were sent
from the pediatric department for routine diagnostics.
Walters et al. used a similar approach and reported a
prevalence of 2.3 % for HPeV among children <3 months
of age, which is in close agreement to our results [2]. In
contrast to other studies, we did not observe a 2-year
seasonality for HPeV [3]. A different epidemiology in
Germany cannot be ruled out but the samples size per
year was rather small and prolonged storage may have in-
fluenced our results. This is supported by another study
from our laboratory where other HPeV types were more
frequently detected in respiratory tract and stool samples
compared to HPeV3 [13].
Of note, both HPeV cases occurred in the fall of 2008,
which contrasts with a report from another European
country, where most infections were seen in the spring
[11]. Recent data from the USA indicate that the peak
season for HPeV detection was in the summer months
[12]. The highly variable epidemiology of HPeV is
supported by recent findings from South Korea, where
the majority of cases were detected in spring in one
study and in summer in another study [14, 15]. However,
both studies covered only a short period of time. Beyond
the detection of HPeV in clinical samples using PCR
seroepidemiological data is urgently needed to better
appreciate the epidemiology and impact of HPeV in
general and of HPeV3 in particular. As expected for EV
we observed a peak of cases in the summer months.
Typing of HPeV samples showed exclusively HPeV3,
which is consistent with other studies. In contrast, typ-
ing of EV samples showed a diversity of EV species B
subtypes. A seroepidemiogical study from France dem-
onstrated the predominance of EV species B from 2000
to 2004 and echovirus 30 was the most frequently
detected EV, which is supported by our data [16].
Noteworthy, similar findings were reported from
Germany [17]. We did not detect EV71 although this
strain is reported to circulate in different European
countries [18, 19]. However, cases of hand, foot, and
mouth disease are typically seen by general practitioners
without laboratory testing. Therefore, information on
EV71 is scarce supporting the notion that monitoring of
EV diversity is an important issue not only for public
health. It has been shown that genotyping can help to
rapidly identify novel types which are associated with
severe disease [5]. Interestingly, the detection of EV and
HPeV has been demonstrated in sewage samples which
might serve as a method to rapidly detect spread of EV
strains [19]. In addition, recombination of EV is a com-
mon event and surveillance of sewage can also detect less
pathogenic EV which otherwise remain unnoticed [19].
Importantly, HPeV3 infections tended towards higher
RNA concentrations compared to infections with EV
although the difference was not statistically significant.
This finding was also seen when only children <3 months
of age where included in the analysis. Of note, both
HPeV samples were obtained significantly later after
symptom onset compared to EV positive samples suggest-
ing even higher HPeV3 RNA concentrations. It is specula-
tive if a missing RGD motif in HPeV3 and a possible
neurotropism account for higher RNA concentrations
[20]. A variation in virulence as proposed in a study may
also be responsible [21]. Besides intrinsic viral factors
recent seroepidemiological studies have demonstrated that
more than 30 % of child-bearing aged women lack anti-
bodies to HPeV3 [22]. Another study showed a low preva-
lence of HPeV3 specific neutralizing antibodies among the
adult Dutch (10 %) and Finnish (13 %) population [23]. Of
note, the authors speculated on difficulties in producing
HPeV3 specific antibodies and the possibility of a test arte-
fact. However, if the lack of passively transferred maternal
HPEV3 antibodies renders neonates vulnerable to infec-
tion remains speculative. In contrast, antibodies to EV are
Table 2 Proportion of clinical characteristics between patients with EV, echovirus 30, non EV-30 EV, and HPeV in CSF samples
Characteristic All EV (n = 14) Echovirus 30 (n = 7) Non EV-30 EV (n = 4) HPeV (n = 2)
Fever/Hypothermia 93 % (13/14) 86 % (6/7) 100 % (4/4) 100 % (2/2)
Meningism 57 % (8/14) 71 % (5/7) 25 % (1/4) 0 % (0/2)
Headache 57 % (8/14) 86 % (6/7) 25 % (1/4) na
Photophobia 21 % (3/14) 29 % (2/7) 0 % (0/4) na
Sepsis-like illness 0 % (0/14) 0 % (0/7) 0 % (0/4) 100 % (2/2)
Aseptic meningitis 86 % (12/14) 86 % (6/7) 100 % (4/4) 0 % (0/2)
Encephalitis 0 % (0/14) 0 % (0/7) 0 % (0/4) 50 % (1/2)
Respiratory tract symptoms 50 % (7/14) 57 % (4/7) 25 % (1/4) 50 % (1/2)
Gastrointestinal symptoms 64 % (9/14) 86 % (6/7) 50 % (2/4) 0 % (0/2)
Rash 0 % (0/14) 0 % (0/7) 0 % (0/4) 50 % (1/2)
na not applicable
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widespread and might prevent EV replication to high
titers. For EV, genotype-dependent RNA concentrations
have been described recently. Volle and colleagues dem-
onstrated higher virus concentration in echovirus 30 cases
compared to those with echovirus six infection [24]. We
could observe a trend to higher RNA concentrations in
echovirus 30 cases but without statistical significance.
Clearly, more patients are needed to confirm our findings.
Interestingly, Harvala et al. reported HPeV RNA
concentrations <500 copies/ml in CSF samples of young
infants submitted for bacterial sepsis screening [25].
From the same study it should be noted that spill-over
of EV and HPeV, with low viral concentration in CSF,
can occur from the blood and the mere detection of
viral RNA in the CSF is not sufficient for a diagnosis of
CSF infection, particularly if other indicative findings of
CNS infection like pleocytosis are absent [25]. Unfortu-
nately, we were not able to systematically retrieve white
cell count in CSF samples as a marker for CNS infection
due to the retrospective nature of the study. However,
they could demonstrate higher RNA concentrations in
blood samples suggesting that this type of sample should
be preferred in sepsis evaluation. Choosing the best
sample type for diagnosis was also addressed by another
study which showed that stool samples were superior
over CSF samples [26]. On the other hand, HPeV was
shown to be also present in stool samples of healthy
children indicating asymptomatic shedding after infec-
tion [27]. From these data it is obvious to alert clinicians
that samples from multiples sites can considerably
increase diagnostic yield. In our retrospective study we
were not able to retrieve corresponding blood samples
from our patients. However, we could show that typing
was positive from stool samples in those patients in
which typing from CSF samples failed for unknown
reasons supporting the notion that multiple samples
prove beneficial. From a technical point, the use of
contemporary PCR assays is highly recommended. We
could show that the detection rate for EV increase by a
quarter upon use of recently published assay [10].
According to Dierssen et al. modifications of the primer
and probe binding sites increased the detection of diver-
gent echovirus 30 strains [10]. It should be noted that
we might have missed cases of HPeV associated CNS
infection due to low HPeV concentrations as virus con-
centrations below 500 copies/ml in CSF samples have
been reported in infants with sepsis-like illness [25].
Conclusions
Here, we could show that HPeV3 infection of the central
nervous system occurs predominantly in young infants.
Unlike for EV only one HPeV type, i.e. HPeV3, was seen.
Higher viral loads in HPeV3 infection might contribute
to severity of illness and deserve further studies. Beyond
the detection and assessment of viral RNA concentra-




A total of 327 archived CSF samples from 327 patients
had been collected from May 1998 until October 2008.
No samples were available from May to September
1999. Specimens were originally submitted to the Insti-
tute of Virology, University Medical Centre Bonn for
routine virological work-up due to suspected meningitis
or encephalitis at the discretion of the treating physician.
Further criteria to obtain CSF samples were other neuro-
logical symptoms, e.g. meningism, bulging fontanella, sei-
zures, reduced vigilance, and late-onset sepsis. Bacterial
testing was not systematically done and thus not reported
here. All samples were anonymized and stored at −20 °C.
Due to prolonged storage no attempts for virus isolation
were made. Residual testing was approved by the ethics
committee of Bonn University Medical Centre.
Nucleic acid extraction
For PCR samples were extracted in pools of five and
tested. In case of a positive finding pools were resolved
and samples were individually re-extracted and tested.
Viral nucleic acids were purified by means of a viral RNA
mini Kit (Qiagen, Hilden, Germany) with minor modifica-
tions. Due to little left-over of samples the input volume
was set to 120 μl, and the elution volume to 100 μl.
Real-time reverse-transcription-PCR (RT-PCR) and
real-time PCR
For EV RNA detection two assays were performed as de-
scribed [9, 10]. For HPeV detection the assays according
to Baumgarte et al. and Nix et al. were used [28, 29]. All
assays were of quantitive nature using RNA transcripts
as described. In brief, amplicons of each real-time
RT-PCR were cloned into pCR4 plasmid vector (Life
Technologies, Karlsruhe, Germany) and in vitro RNA
transcribed using the MEGAScript T7 in vitro transcrip-
tion kit (Life Technologies) [28]. The detection of
cytomegalovirus (CMV), herpes simplex virus 1/2 (HSV),
and varizella zoster-virus (VZV) was done as described
elsewhere [30–32].
EV and HPeV typing
Typing of EV and HPeV was conducted as described
[28, 33]. EV positive samples were sequenced in the
VP2 gene [33]. For HPeV the complete VP1 region
including the RGD motif and the VP3/VP1 junction
region was sequenced according to Haravla et al. [3].
Sequencing was done on an ABI Prism 3130 using
the Big-Dye Terminator kit (Applied Biosystems,
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Weiterstadt, Germany). Sequences were analyzed
using Bio-Edit and by comparison with published
sequences in NCBI GenBank.
Statistics
Statistical analysis was performed using the GraphPad
Prism 6 software package (Graphpad, La Jolla, CA, USA).
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